Simulations Plus, Inc.

As of July 14, 2025, Simulations Plus, Inc. is considered risky and overvalued, with a high P/E ratio of 107 and poor stock performance, reflected in a year-to-date return of -43.13%, compared to the S&P 500's 12.22%.

Simulations Plus, Inc. reported its financial results for the quarter ending May 2025, highlighting significant improvements in key metrics. The company achieved a pre-tax profit of USD 3.18 million, a record debtors turnover ratio of 4.9, and a net profit of USD 9.9 million, indicating strong operational efficiency and profitability.

As of July 8, 2024, Simulations Plus, Inc. is considered very expensive and overvalued, with a P/E ratio of 107 and significant declines in stock performance, contrasting sharply with industry peers and the S&P 500.

As of June 3, 2025, Simulations Plus, Inc. has shifted to a bearish trend, indicated by negative MACD readings, bearish Bollinger Bands, and underperformance relative to the S&P 500.

As of March 2022, the management team of Simulations Plus, Inc. includes Chairman Walter Woltosz and independent directors Dr. Lisa LaVange, Dr. John Paglia, Dr. David Ralph, and Dr. Daniel Weiner.

Simulations Plus, Inc. develops software for drug discovery and development, with recent net sales of $22 million and a net profit of $3 million. The company has a market cap of $368.43 million and key metrics include a P/E ratio of 107.00 and a dividend yield of 0.32%.

As of Jun 18, Simulations Plus, Inc. has a market capitalization of 368.43 million, with net sales of 78.55 million and a net profit of 7.26 million over the latest four quarters. The balance sheet as of Aug 24 shows shareholder's funds of 182.43 million and total assets of 207.64 million.